search
Back to results

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

Primary Purpose

Airway Inflammation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
placebo
Montelukast
Sponsored by
Marywood University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Airway Inflammation focused on measuring particulate air pollution, leukotriene, asthma, montelukast, vascular endothelial dysfunction, nitric oxide(NO)endothelin (ET) system

Eligibility Criteria

18 Years - 30 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male subjects
  • between 18 and 30 years of age
  • participant in endurance sport

Exclusion Criteria:

  • history of blood clotting
  • history of coagulation problems
  • History of spontaneous pneumothorax

Sites / Locations

  • Marywood University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Placebo Comparator

Experimental

Experimental

Arm Label

1

2

3

4

Arm Description

Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.

Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.

Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.

Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.

Outcomes

Primary Outcome Measures

Exposure to airborne ultrafine and fine particulate matter causes vascular dysfunction.

Secondary Outcome Measures

Montelukast protects against pollution induced vascular dysfunction.

Full Information

First Posted
December 22, 2008
Last Updated
May 20, 2009
Sponsor
Marywood University
search

1. Study Identification

Unique Protocol Identification Number
NCT00814281
Brief Title
Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?
Official Title
Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?
Study Type
Interventional

2. Study Status

Record Verification Date
May 2009
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
May 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Marywood University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to examine biological pathways of altered blood vessel function resulting from breathing airborne particulate. Blood artery function in healthy men will be measured after particulate exposure either on placebo or on an asthma medication that stops production of an inflammatory biological agent. Lung and blood profiles will be obtained before and after exposure to exhaust fumes. We believe that the inflammatory agent produced by the lungs from breathing these particles causes abnormal artery function.
Detailed Description
Hourly ice resurfacing by gas and propane fueled machines creates high levels of ultrafine and fine particulate matter (PM1) in indoor ice rinks. PM1 exposure may disrupt the normal nitric oxide (NO)/endothelin (ET)-1 vasodilation system and promote atherosclerosis, and/or increase the risk of an acute cardiac event. Our specific aims are 1) to determine whether impaired endothelial-mediated vasodilation and forearm muscle tissue reoxygenation rate and blood volume change (to reactive hyperemia following artery occlusion) is associated with combustion-derived PM1 exposure, and 2) To characterize a PM1 induced mechanism of endothelial dysfunction which occurs via a leukotriene (LT)-associated, airway generated tumor necrosis factor-alpha (TNF-a) mediated pathway. Healthy low PM1 exposed males will be evaluated for endothelial dysfunction before and after artery occlusion using high resolution ultrasound and near-infrared spectroscopy (NIRS), before and after moderate exercise in blinded high and low [PM1]. Endothelial dysfunction among chronically PM¬1 exposed ice rink athletes will be determined to evaluate the feasibility of using this population as a model in future studies. TNF-a, IL-8, LTB4, LTC4, LTD4, LTE4, ET-1, NO, and differential cell counts will be measured in sputum and serum. [PM1] will be monitored and exposure levels will be typical of indoor ice rinks. LT involvement will be assessed in vivo by double-blind pharmacological manipulation during PM1 exposure during light exercise. Results will demonstrate whether endothelial-mediated vasodilation and muscle hemodynamics are influenced by PM1 exposure, and will elucidate an LT initiated TNF-a mediated pathway in ET-1 upregulation. Our results should provide information for understanding the effects of PM1 exposure on the atherosclerotic process and cardiovascular risk, and give insight to novel treatment and diagnostic modalities.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Airway Inflammation
Keywords
particulate air pollution, leukotriene, asthma, montelukast, vascular endothelial dysfunction, nitric oxide(NO)endothelin (ET) system

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Placebo Comparator
Arm Description
Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
Arm Title
3
Arm Type
Experimental
Arm Description
Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
Arm Title
4
Arm Type
Experimental
Arm Description
Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
Intervention Type
Other
Intervention Name(s)
placebo
Other Intervention Name(s)
Sugar Pill
Intervention Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Montelukast
Other Intervention Name(s)
Singulair
Intervention Description
10 mg ingested orally 1 hour prior to exercise testing
Primary Outcome Measure Information:
Title
Exposure to airborne ultrafine and fine particulate matter causes vascular dysfunction.
Time Frame
February 2009
Secondary Outcome Measure Information:
Title
Montelukast protects against pollution induced vascular dysfunction.
Time Frame
February 2009

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male subjects between 18 and 30 years of age participant in endurance sport Exclusion Criteria: history of blood clotting history of coagulation problems History of spontaneous pneumothorax
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenneth W Rundell, PhD
Organizational Affiliation
Marywood University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Marywood University
City
Scranton
State/Province
Pennsylvania
ZIP/Postal Code
18509
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

We'll reach out to this number within 24 hrs